Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

S-Adenosyl-l-methionine restores brain mitochondrial membrane fluidity and GSH content improving Niemann-Pick type C disease

  • Goicoechea, Leire
  • Torres, Sandra
  • Fábrega Jiménez, Laura
  • Barrios, Mónica
  • Núñez, Susana
  • Casas, Josefina
  • Fabriàs, Gemma
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Niemann-Pick type C (NPC) disease is a lysosomal storage disorder characterized by impaired motor coordination due to neurological defects and cerebellar dysfunction caused by the accumulation of cholesterol in endolysosomes. Besides the increase in lysosomal cholesterol, mitochondria are also enriched in cholesterol, which leads to decreased membrane fluidity, impaired mitochondrial function and loss of GSH, and has been shown to contribute to the progression of NPC disease. S-Adenosyl-l-methionine (SAM) regulates membrane physical properties through the generation of phosphatidylcholine (PC) from phosphatidylethanolamine (PE) methylation and functions as a GSH precursor by providing cysteine in the transsulfuration pathway. However, the role of SAM in NPC disease has not been investigated. Here we report that Npc1-/- mice exhibit decreased brain SAM levels but unchanged S-adenosyl-l-homocysteine content and lower expression of Mat2a. Brain mitochondria from Npc1-/- mice display decreased mitochondrial GSH levels and liquid chromatography-high resolution mass spectrometry analysis reveal a lower PC/PE ratio in mitochondria, contributing to increased mitochondrial membrane order. In vivo treatment of Npc1-/- mice with SAM restores SAM levels in mitochondria, resulting in increased PC/PE ratio, mitochondrial membrane fluidity and subsequent replenishment of mitochondrial GSH levels. In vivo SAM treatment improves the decline of locomotor activity, increases Purkinje cell survival in the cerebellum and extends the average and maximal life spam of Npc1-/- mice. These findings identify SAM as a potential therapeutic approach for the treatment of NPC disease., Carmen Garcia-Ruiz and Jose C Fernandez-Checa belong to the Spanish National Researh Council's Cancer Hub. We are grateful for the support from grants PID2019-111669RB-100, PID2020-115055 R B-I00, PID2022-1429560B–I00 and 2023AEP068 from Plan Nacional de I + D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the Generalitat de Catalunya SGR-2021-00491, European Cooperation in Science & Technology (COST) ACTION CA17112, Prospective European Drug- Induced Liver Injury Network, the 2018-102799-T “Enfermedades Metabólicas y Cancer” from the Red Nacional of the Spanish Health Ministry and the COVID grant from the Spanish Association for the Study of the Liver (AEEH). In addition, this project has received funding from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 and TOGETHER STRONG NPC FOUNDATION USA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network

  • Segovia-Zafra, Antonio
  • Villanueva-Paz, Marina
  • Serras, Ana Sofia
  • Matilla-Cabello, Gonzalo
  • Bodoque-García, Ana
  • Di Zeo-Sánchez, Daniel E.
  • Niu, Hao
  • Álvarez-Álvarez, Ismael
  • Sanz-Villanueva, Laura
  • Godec, Sergej
  • Milisav, Irina
  • Bagnaninchi, Pierre
  • Andrade, Raúl J.
  • Lucena, M Isabel
  • Fernández-Checa, José C.
  • Cubero, Francisco Javier
  • Miranda, Joana Paiva
  • Nelson, Leonard J.
Idiosyncratic drug-induced liver injury (DILI) is a complex and unpredictable event caused by drugs, and herbal or dietary supplements. Early identification of human hepatotoxicity at preclinical stages remains a major challenge, in which the selection of validated in vitro systems and test drugs has a significant impact. In this systematic review, we analyzed the compounds used in hepatotoxicity assays and established a list of DILI-positive and -negative control drugs for validation of in vitro models of DILI, supported by literature and clinical evidence and endorsed by an expert committee from the COST Action ProEuroDILI Network (CA17112)., This work was supported by grants from the Instituto de Salud Carlos III and Consejería de Salud de Andalucía, cofounded by Fondo Europeo de Desarrollo Regional (FEDER) (PI21/01248, PI19-00883, PT23/00137, PEMP-0127-2020, PI-0310-2018) and Agencia Española del Medicamento y Productos Sanitarios. M.V.P and I.A.A. hold Sara Borrell contracts (CD21/00198 and CD20/00083, respectively). H.N. holds a postdoctoral contract (POSTDOC_21_00780). A.S.Z. holds a Jaume Bosch predoctoral contract funded by CIBERehd (CECO-EHD002). D.D.S. holds an iPFIS predoctoral contract funded by ISCIII (IFI21/0034). G.M.C. holds an FPU PhD fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU22/03868). SCReN and CIBERehd are funded by ISCIII. A.S.S. holds a research scholarship funded by Fundação para a Ciência e a Tecnologia (2021.04902.BD). This publication is based on work from COST Action ‘CA17112 Prospective European Drug-Induced Liver Injury Network’ supported by COST (European Cooperation in Science and Technology); www.cost.eu. We acknowledge the support from grants PID2019-111669RB-100, PID2022-1429560B-I00 and PID2023AEP068 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI), FEDER and from the CIBEREHD; as well as funding by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679; UKRI Horizon Europe Grant 10067052, and support from AGAUR of the Generalitat de Catalunya SGR-2021-00491, and from the Project 201916/31 funded by Fundació Marató TV3. Funding for open access charge: Universidad de Málaga/CBUA., Peer reviewed